Companies › iCell Gene Therapeutics
3 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 2; Oncology, Hematology, Immunology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ICG318 BCMA-CD19 dual-targeting CAR-T cells with IL-15/IL-15 sushi domain | TNFRSF17, CD19, BCMA | Phase 2 | Systemic Lupus Erythematosus (SLE); Inflammatory Myopathy | Dec 2027 |
| BCMA-CD19 cCAR T cells Dual-targeted CAR T cell therapy targeting BCMA and CD19 expressed on B cells and plasma c | BCMA, CD19 | Phase 1 | Multiple Myeloma in Relapse; Refractory Immune Cytopenia | Apr 2027 |
| Anti-CD33-CLL1 CAR-T cells (ICG415) Autologous CAR-T cells targeting CD33 and CLL1 | – | Phase 1 | Acute Myeloid Leukemia (AML) | Jul 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04162353 | BCMA-CD19 cCAR T cells | Phase 1 | Multiple Myeloma in Relapse | Oncology | Jul 2026 |
| NCT06787989 | BCMA-CD19 cCAR T cells | Phase 1 | Refractory Immune Cytopenia | Hematology | Apr 2027 |
| NCT07715136 | ICG318 | Phase 1 | Inflammatory Myopathy | Immunology | Dec 2027 |
| NCT07668557 | Anti-CD33-CLL1 CAR-T cells (ICG415) | Phase 1 | Acute Myeloid Leukemia (AML) | Oncology | Jul 2028 |
| NCT07328581 | ICG318 | Phase 2 | Systemic Lupus Erythematosus (SLE) | Immunology | Dec 2028 |
Juventas Cell Therapy Beijing Yongtai Ruike Biotechnology Company Hrain Biotechnology Jiangsu Topcel-KH Pharmaceutical Hebei Senlang Biotechnology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.